Medically reviewed by Susan Bard, MD Alopecia areata is a common hair loss condition. It affects people of all ages, races, ...

Discover management strategies for alopecia areata, from anti-inflammatory diets to stress reduction techniques that can help ...

While similarities exist between types of alopecia, distinct clinical characteristics help patients & physicians ...

Retail investor interest in Q32 Bio Inc picked up on Wednesday after the clinical-stage biotech said the U.S. Food and Drug ...

The Food and Drug Administration (FDA) has granted Fast Track designation to bempikibart for the treatment of alopecia areata (AA).

Significant unmet needs were found among high-quality validation studies on the internal structure of patient-reported ...

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, ...

When it comes to the world of hair loss, it’s no question that the amount of information out there can feel extremely ...

USA: In a significant advancement for the treatment of severe alopecia areata (AA), long-term data from two phase III clinical trials-BRAVE-AA1 and BRAVE-AA2-have confirmed that ...

has granted Fast Track designation to bempikibart for the treatment of Alopecia Areata (AA), an autoimmune disease that attacks hair follicles causing patchy hair loss. Fast Track is a process ...

Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program.

Bempikibart (ADX-914) is a human anti-IL-7Rα antibody that blocks the IL-7 and TSLP pathways, which have been implicated in driving T cell-mediated pathological processes in autoimmune diseases.